Treatments for autoimmune diseases have big shortcomings, including high cost and supply shortages. A alternative developed this year from the #RavetchLab achieves the same effectiveness at a fraction of the dose. #RockefellerScience #YearInReview

🔗: https://bit.ly/3HFdsbs

Researchers in the #RavetchLab have developed a potential replacement for treating #autoimmunedisease that’s significantly more potent than intravenous immunoglobulin therapy.

Learn more in this Q&A with Jeffrey Ravetch and first author Andrew Jones: https://bit.ly/3KTnzLy

Researchers develop a potential IVIG replacement for treating autoimmunity that's significantly more potent - News The discovery could greatly improve patient experience and address supply shortages.

Current treatments for autoimmune diseases have significant shortcomings, including high cost and supply shortages. A new alternative from the #RavetchLab achieves the same effectiveness when tested in mice at a fraction of the dose. @science.org

Immunotherapy drug eliminates aggressive cancers in clinical trial - News The researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.

Published in @cp-cancercell.bsky.social, the #RavetchLab demonstrates in a phase 1 clinical trial that an engineered antibody improves a class of cancer drugs—called CD40 agonist antibodies—that has struggled to make good on its early promise. #RockefellerScience